An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patients with long-term disease control. High Dose Aldesleukin/Recombinant Interleukin-2 (HD rIL-2) and ipilimumab (IPI) offer complementary mechanisms against MM. This phase IV study assessed the sequenced...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasanov, Merve, Milton, Denái R., Sharfman, William H., Taback, Bret, Cranmer, Lee D., Daniels, Gregory A, Flaherty, Lawrence, Hallmeyer, Sigrun, Milhem, Mohammed, Feun, Lynn, Hauke, Ralph, Doolittle, Gary, Gregory, Nancy, Patel, Sapna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510610/
https://www.ncbi.nlm.nih.gov/pubmed/34650833
http://dx.doi.org/10.1080/2162402X.2021.1984059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510610/
https://www.ncbi.nlm.nih.gov/pubmed/34650833
http://dx.doi.org/10.1080/2162402X.2021.1984059

Ejemplares similares